AnaptysBio (NASDAQ:ANAB) Reaches New 52-Week Low at $19.32

AnaptysBio, Inc. (NASDAQ:ANABGet Rating) reached a new 52-week low on Wednesday . The company traded as low as $19.32 and last traded at $19.32, with a volume of 4579 shares changing hands. The stock had previously closed at $19.98.

A number of research analysts recently issued reports on ANAB shares. StockNews.com downgraded AnaptysBio from a “hold” rating to a “sell” rating in a report on Tuesday, April 26th. Zacks Investment Research raised AnaptysBio from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 17th. Guggenheim cut AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Tuesday, March 22nd. Wedbush reaffirmed a “neutral” rating on shares of AnaptysBio in a research report on Monday, March 14th. Finally, HC Wainwright increased their price target on AnaptysBio from $43.00 to $46.00 and gave the company a “buy” rating in a report on Monday, March 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $40.00.

The stock’s fifty day moving average is $23.57 and its 200 day moving average is $29.10. The stock has a market cap of $539.20 million, a P/E ratio of -7.02 and a beta of 0.17.

AnaptysBio (NASDAQ:ANABGet Rating) last announced its quarterly earnings data on Wednesday, May 4th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.32). AnaptysBio had a negative return on equity of 20.44% and a negative net margin of 143.46%. As a group, research analysts expect that AnaptysBio, Inc. will post -4.27 EPS for the current fiscal year.

In related news, major shareholder Ecor1 Capital, Llc acquired 668,237 shares of the stock in a transaction dated Thursday, May 5th. The stock was acquired at an average cost of $21.63 per share, for a total transaction of $14,453,966.31. Following the completion of the purchase, the insider now owns 7,521,024 shares of the company’s stock, valued at approximately $162,679,749.12. The purchase was disclosed in a document filed with the SEC, which is available through this link. 34.90% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of the company. Amundi Pioneer Asset Management Inc. acquired a new stake in AnaptysBio in the 1st quarter valued at about $110,000. Dorsey Wright & Associates purchased a new stake in AnaptysBio in the fourth quarter valued at $54,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in AnaptysBio by 48.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,749 shares of the biotechnology company’s stock valued at $68,000 after acquiring an additional 898 shares during the last quarter. Lazard Asset Management LLC increased its stake in AnaptysBio by 60.1% in the fourth quarter. Lazard Asset Management LLC now owns 3,589 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 1,347 shares during the period. Finally, BNP Paribas Arbitrage SA increased its stake in AnaptysBio by 79.7% in the third quarter. BNP Paribas Arbitrage SA now owns 5,009 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 2,222 shares during the period.

About AnaptysBio (NASDAQ:ANAB)

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

See Also

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.